Court grants AstraZeneca prelim injunction against Apotex over Pulmicort
On May 20, the US District Court for the District of New Jersey granted Anglo-Swedish drug major AstraZeneca's request for an injunction barring Canadian firm Apotex from launching a generic version of AstraZeneca's Pulmicort Respules (budesonide inhalation suspension) in the USA. No trial date for the patent litigation has been set.
On 30 March, the US Food and Drug Administration granted approval for a generic version of Pulmicort Respules to Apotex. AstraZeneca then filed suit following Apotex' indication of intent to market a generic version of the drug in the USA prior to the expiration of AstraZeneca's patents. The UK-based firm says it has full confidence in the strength of its intellectual property rights protecting the asthma medication and will continue to vigorously defend and enforce its IP. Patents covering Pulmicort Respules expire in 2018 with pediatric exclusivity extending to 2019, the firm notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze